At CSI, we’re on a mission to improve healthcare access and care for coronary artery disease (CAD) and peripheral artery disease (PAD). We’re on a mission to educate patients and physicians. We’re on a mission to improve access and patient outcomes and to deliver value. We collaborate with providers and policy makers to help ensure fair and accurate reimbursement for treatment.
We support groundbreaking research as well as its subsequent publication and presentation to the healthcare community. CSI leaders present at the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) each year.
CSI is a proud supporter of the CardioVascular Coalition, and we continually seek out like-minded industry groups to advance CAD and PAD treatment.
At CSI, we’re dedicated to helping reduce severe arterial calcium and enable successful stent delivery to help optimize stent expansion and PCI outcomes. Much of the research surrounding endovascular treatments for CAD exclude patients with severely calcified lesions.
At CSI, we’re focused on developing solutions for this difficult-to-treat population and studying the effectiveness and patient outcomes using orbital atherectomy technology.
Peripheral artery disease (PAD) affects up to 18 million people in the US, according to estimates.22 And the numbers will continue to increase:
Some studies suggest that African-Americans may not feel the symptoms as early as Caucasians, therefore they do not seek treatment as early.34
CSI seeks to identify racial and ethnic disparities in PAD treatment through our dedicated research and legislative advocacy efforts.
African-Americans & Hispanics are 2X as likely to be amputated as Caucasians29
Analysis of amputation rates for the treatment of patients with a primary diagnosis of PAD, using the Healthcare Cost and Utilization Project (HCUP) inpatient database from 2006-2013.
Clinical research supports our goal of informing health policy. We seek to understand the disease state and patient factors. We find ways to help save limbs and advocate for better access to care in the African-American, Hispanic and Native American communities.
Important findings of our recent research determine that:
• Introduced New Reimbursement/Procedure Codes
• Promoted International Efforts
• Supported OEIS
• Supported Coding to Increase Medicare Payments
• Helped Create Cardiovascular Coalition
• Proposed CLI/Amputation Payment Model
• Helped Form CLI Medical Society
• Met With CMS
• Presented to (MEDCAC)
• Worked with CMS on Mandated Screening Strategy
• Worked with Congress on PAD Medicare Coverage Legislation
The CardioVascular Coalition (CVC) understands that PAD is a leading and preventable cause of death in the US. CSI – along with national physician, provider and advocacy organizations – created the CVC to improve the awareness of and prevention of PAD.
As a coalition, we will secure patient access to high-quality, cost-effective interventional treatment for PAD. To help achieve this goal, the CVC currently operates 211 CardioVascular Centers in 31 states.
The CSI team is committed to assisting healthcare policymakers and healthcare providers in evaluating the economic impact of utilizing orbital atherectomy technology. Our team can provide the background and resources you need to evaluate procedures.
Analysis of cost-effectiveness of treatment with orbital atherectomy
CSIQ is the official medical education program of Cardiovascular Systems, Inc. Our goal is for you to use this information to better understand the prevalence of arterial calcium and how to treat it using our Orbital Atherectomy Systems. From group courses taught by leading orbital atherectomy experts to personalized, one-on-one proctorships, CSIQ demonstrates the value and procedural efficiency of our Orbital Atherectomy Systems. Clinical data that underscore the safety, efficacy and long-term durability of the devices is also provided.